Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Trial

Cancer Hospital of Guangxi Medical University40 enrolled

Overview

This is a prospective, single-arm, phase II trial to study the efficacy of PD-1 antibody Toripalimab combined with concurrent cisplatin chemoradiotherapy in treating patients with locoregionally recurrent nasopharyngeal carcinoma.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Nasopharyngeal Carcinoma Toripalimab Recurrent Nasopharyngeal Squamous Cell Carcinoma

Interventions

ToripalimabDRUG

Toripalimab 240mg every 3 weeks with a total of 3 cycles as concurrent anti-PD-1 immunotherapy; Toripalimab240mg every 3 weeks with a total of 9 cycles as adjuvant anti-PD-1 immunotherapy 2 weeks after CCRT

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients with newly histologically confirmed recurrent nasopharyngeal carcinoma, or Two or more image examinations (MRI, and PET-CT) show the recurrence tumor 2. staged as rT3-4N0-1M0或rT1-4N2-3M0 （according to the 8th AJCC edition） 3. Satisfactory performance status: ECOG (Eastern Cooperative OncologyGroup) scale 0-1 4. Neutrophil ≥ 1.5×109 /L and PLT ≥4×109 /L and HGB ≥90 g/L 5. With normal liver function test (ALT、AST ≤ 2.5×ULN, TBIL≤ 1.5×ULN) 6. With normal renal function test ( creatinine clearance ≥60 ml/min) 7. sign an "informed consent form 8. Male and no pregnant female Exclusion Criteria: 1. Age\> 70, or \< 18 years old 2. Hepatitis B surface antigen (HBsAg) positive and HBV-DNA ≥200IU/ml, or 1000cps/ml. 3. Patients with positive HCV antibody. 4. Active, known or suspected autoimmune disease; Type I Diabetes, hypothyroidism those only need hormone replacement therapy, and skin disease (leukoderma, psoriasis, alopecia et al) who don't need systemic therapy can recruit. 5. History of interstitial lung disease 6. Equivalent dose more than prednisone 10mg/d or other immunosuppressive treatments within 28 days prior to signing the informed consent. 7. Receive or will receive live vaccine within 30 days prior to signing the informed consent. 8. Women of child-bearing potential who are pregnant or breastfeeding. 9. Suffered from malignant tumors, except the carcinoma in situ, papillary thyroid carcinoma, or skin cancer (non- melanoma) within five years. 10. Hypersensitivity to macromolecular protein, or to any component of triplezumab. 11. HIV positive. 12. Severe, uncontrolled medical conditions and infections. 13. Other diseases which may influence the safety or compliance of the clinical trial, such as heart failure with symptom, unstable angina, myocardial infarction, active infections those need systemic therapy, mental illness, or their family and society factors.

Locations (1)

Guangxi Medical University Cancer Hospital

Nanning, Guangxi, China

RECRUITING

Outcomes

Primary Outcomes

Overall survival

Defined from date of randomization to date of first documentation of death from any cause or censored at the date of the last follow-up.

Time frame: 2 years

Secondary Outcomes

Progress-free survival (PFS)

Defined from date of randomization to date of first documentation of progression or death due to any cause.

Time frame: 2 years

Objective Response Rate （ORR）

An objective response is defined as either a confirmed CR or a PR, as determined by the investigator using RECIST v1.1Response Evaluation Criteria in Solid Tumors (RECIST) from the National Cancer Institute (NCI).

Time frame: After the completion of the PD-1 antibody and chemoradiotherapy treatment

Incidence rate of adverse events (AEs)

Analysis of adverse events (AEs) are based on treatment-related AEs (trAEs) and immune-related AEs (irAEs), and all-grade AEs and grade 3-4 AEs. AEs are evaluated by investigators according to the Common Terminology Criteria for Adverse Events, version 5.0

Time frame: 2 years

Change of QoL (quality of life)

QoL scores were assessed by using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTCQLQ-C30) before radiotherapy, at the end of radiotherapy, at 12 months after radiotherapy.

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.